Perl Highlights Practice-Changing Data for Gilteritinib in Relapsed/Refractory AML - Targeted Oncology https://t.co/Qa0Mra2n3e
— IDRO (@IDROOhio) May 4, 2019
from Twitter https://twitter.com/IDROOhio
May 03, 2019 at 11:56PM
Saturday, May 4, 2019
Perl Highlights Practice-Changing Data for Gilteritinib in Relapsed/Refractory AML - Targeted Oncology https://t.co/Qa0Mra2n3e
from Twitter https://twitter.com/IDROOhio
May 03, 2019 at 11:56PM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment